Class of 2024
For trailblazing research involving the use of small molecules to manipulate intracellular protein levels via targeted protein degradation, pioneering the development of proteolysis-targeting chimeras (PROTACs), and leading critical investigations concerning synthetic proteasome inhibitors such as carfilzomib, approved for the treatment of multiple myeloma.
*Full-length biography pending